Diagnosis of infection of implantable central venous catheters by [f]fluorodeoxyglucose positron emission tomography

Nuclear Medicine Communications

Volumn 25, Issue 8, 2004, Pages 813-818

  Miceli, Marisa H ^a   Jones Jackson, Laurie B ^a   Walker, Ronald C ^a   Talamo, Giampaolo ^a   Barlogie, Bart ^a   Anaissie, Elias J ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

FDG PET; Implantable central venous catheter; Infection

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; ARTICLE; CATHETER INFECTION; CENTRAL VENOUS CATHETER; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DEVICE REMOVAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DRUG UPTAKE; FEMALE; HUMAN; INFLAMMATION; MALE; MULTIPLE MYELOMA; NEUTROPENIA; POSITRON EMISSION TOMOGRAPHY; SAFETY;

ADULT; ANTINEOPLASTIC AGENTS; CATHETERIZATION, CENTRAL VENOUS; CROSS INFECTION; FEASIBILITY STUDIES; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PILOT PROJECTS; POSITRON-EMISSION TOMOGRAPHY; PROSTHESIS-RELATED INFECTIONS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; THROMBOPHLEBITIS;

EID: 4143116644     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/01.mnm.0000130247.37315.66     Document Type: Article

References (20)

1. Biffi R, de Braud F, Orsi F, Pozzi S, Mauri S, Goldrisch A, et al. Totally implantable central venous access ports for long-term chemotherapy. A prospective study analyzing complications and costs of 333 devices with a minimum follow-up of 180 days. Ann Oncol 1998; 9:767-773.
2. Barnes JR, Lucas N, Broadwater JR, Hauer-Jensen M. When should the ‘infected’ subcutaneous infusion reservoir be removed? Am Surg 1996; 62:203-206.
3. Viscoli C. The evolution of the empirical management of fever and neutropenia in cancer patients. J Antimicrob Chemother 1998; 41(suppl D):65-80.
4. Mermel L, Farr B, Sherertz R, Raad I, O'Grady N, Harris J. Guidelines for the management of intravascular catheter-related infections. Clin Infect Dis 2001; 32:1249-1272.
5. Douard MC, Arlet G, Longuet P, Troje C, Rouveau M, Ponscarme D, Eurin B. Diagnosis of venous access port-related infections. Clin Infect Dis 1999; 29:1197-1202.
6. Longuet P, Douard MC, Arlet G, Molina JM, Benoit C, Leport C. Venous access port-related bacteremia in patients with acquired immunodeficiency syndrome or cancer: the reservoir as a diagnostic and therapeutic tool. Clin Infect Dis 2001; 32:1776-1783.
7. Sugawara Y. Infection and inflammation. In: Wahl R, Buchanam J. (editors). Principles and Practice of Positron Emission Tomography, first edition, vol 1. Philadelphia: Lippincott Williams & Wilkins; 2002, pp. 381-394.
8. Stumpe KD, Dazzi H, Schaffner A, von Schulthess GK. Infection imaging using whole-body FDG-PET. Eur J Nucl Med 2000; 27:822-832.
9. Zhuang H, Alavi A. 18-Fluorodeoxyglucose positron emission tomographic imaging in the detection and monitoring of infection and inflammation. Semin Nucl Med 2002; 32:47-59.
10. Rennen H, Boerman O, Oyen W, Corstens F. Imaging infection/inflammation in the new millennium. Eur J Nucl Med 2001; 28:241-252.
11. Miceli M, Atoui R, Walker R, Mahfouz T, Mirza N, Diaz J, et al. Diagnosis of deep septic thrombophlebitis in cancer patients by fluorine-18 flurodeoxyglucose positron emission tomography scanning: a preliminary report. J Clin Oncol 2004; 22:1949-1956.
12. Bayer AS, Scheld MW. Endocarditis and intravascular infections. In: Gerald L, Mandell JEB, Dolin R. (editors). Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, fifth edition, vol 1. Philadelphia: Churchill Livingstone; 2000, pp. 857-902.
13. Sickles EA, Greene WH, Wiernik PH. Clinical presentation of infection in granulocytopenic patients. Arch Intern Med 1975; 135:715-719.
14. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Cala T. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34:730-751.
15. Hamilton H, Fermo K. Assessment of patients requiring i.v. therapy via a central venous route. Br J Nurs 1998; 7:451-454 and 456-460.
16. Carey PJ. Drug-induced myelosuppression: diagnosis and management. Drug Safety 2003; 26:691-706.
17. Mettler F, Guiberteau M. Inflammation and infection imaging. In: Mettler F. (editor). Essentials of Nuclear Medicine Imaging, fourth edition, vol 1. Philadelphia: W.B. Saunders Company; 1998, pp. 387-403.
18. Gibel U, Hartshorne MF, Tzamaloukas AH. Indium-111 oxine leukocyte scan in the diagnosis of peritoneal catheter tunnel infections. Perit Dial Int 1998; 18:234-235.
19. Wahl R. Principles of cancer imaging with fluorodeoxyglucose. In: Wahl R. (editor). Positron Emission Tomography, first edition, vol 1. Philadelphia: Lippincott Williams & Wilkins; 2002, pp. 100-110.
20. Antoch G, Vogt FM, Freudenberg LS, Nazarade H, Goehde SC, Barkhausen J, et al. Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. JAMA 2003; 290:3199-3206.